Xeris Pharmaceuticals, Inc. (XERS): Price and Financial Metrics

Xeris Pharmaceuticals, Inc. (XERS)

Today's Latest Price: $4.73 USD

0.03 (0.53%)

Updated Feb 20 8:37am

Add XERS to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 215 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

XERS Stock Summary

  • Xeris Pharmaceuticals Inc's stock had its IPO on June 21, 2018, making it an older stock than merely 2.68% of US equities in our set.
  • With a price/sales ratio of 98.76, Xeris Pharmaceuticals Inc has a higher such ratio than 97.79% of stocks in our set.
  • Revenue growth over the past 12 months for Xeris Pharmaceuticals Inc comes in at -30.94%, a number that bests only 6.09% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to XERS, based on their financial statements, market capitalization, and price volatility, are NWBO, QTNT, SPPI, RMBS, and KPTI.
  • Visit XERS's SEC page to see the company's official filings. To visit the company's web site, go to www.xerispharma.com.
XERS Daily Price Range
XERS 52-Week Price Range

XERS Stock Price Chart More Charts

XERS Price/Volume Stats

Current price $4.73 52-week high $12.98
Prev. close $4.70 52-week low $3.84
Day low $4.73 Volume 2,150
Day high $4.73 Avg. volume 578,431
50-day MA $6.45 Dividend yield N/A
200-day MA $9.29 Market Cap 127.69M

Xeris Pharmaceuticals, Inc. (XERS) Company Bio

Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company’s lead product candidate is glucagon rescue pen, which has completed Phase III clinical trials for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise self-administered glucagon that is in Phase IIa clinical trials for the treatment of post-bariatric hypoglycemia; continuous glucagon, which is in Phase II clinical trials for the treatment of congenital hyperinsulinism; continuous glucagon that is in Phase IIa clinical trials for the treatment of hypoglycemia-associated autonomic failure; self-administered glucagon, which is in Phase IIa clinical trials for the treatment of exercise-induced hypoglycemia; and ready-to-use glucagon that is in Phase II clinical trials for use in a bi-hormonal artificial pancreas closed-loop systems. The company’s preclinical programs include ready-to-use diazepam, a ready-to-use diazepam formulation for the treatment of ARS in patients with epilepsy; and pram-insulin, a ready-to-use fixed dose combination of insulin and pramlintide. It serves patients, caregivers, and health practitioners. The company was founded in 2005 and is based in Chicago, Illinois.

XERS Latest News Stream

Event/TimeNews Detail
Loading, please wait...

XERS Latest Social Stream

Loading social stream, please wait...

View Full XERS Social Stream

XERS Price Returns

1-mo -22.96%
3-mo -41.68%
6-mo -56.24%
1-year -51.93%
3-year N/A
5-year N/A
YTD -32.91%
2019 -58.53%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.9139 seconds.